Is KYNB or SNTI more profitable?

Kyntra Bio has a net margin of 2,199.13% compared to Senti Biosciences' net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Senti Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Kyntra Bio 2,199.13% N/A -47.27% Senti Biosciences N/A -1,629.80% -119.72%

Is CNTX or SNTI more profitable?

Context Therapeutics' return on equity of -82.06% beat Senti Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Context Therapeutics N/A -82.06% -72.74% Senti Biosciences N/A -1,629.80% -119.72%

Senti Biosciences (SNTI) Competitors

$0.32 +0.01 (+2.24%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.32 0.00 (-0.31%)

As of 09/18/2026 07:34 PM Eastern

Compare

SNTI vs. MDXH, KYNB, CNTX, ALGS, and GOSS

Should you buy Senti Biosciences stock or one of its competitors? Senti Biosciences's main competitors and comparable companies include MDxHealth (MDXH), Kyntra Bio (KYNB), Context Therapeutics (CNTX), Aligos Therapeutics (ALGS), and Gossamer Bio (GOSS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Senti Biosciences compare to MDxHealth?

Senti Biosciences (NASDAQ:SNTI) and MDxHealth (NASDAQ:MDXH) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk.

25.7% of Senti Biosciences shares are held by institutional investors. 3.1% of Senti Biosciences shares are held by insiders. Comparatively, 1.7% of MDxHealth shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Senti Biosciences currently has a consensus price target of $10.00, indicating a potential upside of 3,025.00%. MDxHealth has a consensus price target of $2.17, indicating a potential upside of 243.92%. Given Senti Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Senti Biosciences is more favorable than MDxHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Senti Biosciences has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. MDxHealth's return on equity of 0.00% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-1,629.80%	-119.72%
MDxHealth	-33.46%	N/A	-24.25%

In the previous week, MDxHealth had 1 more articles in the media than Senti Biosciences. MarketBeat recorded 1 mentions for MDxHealth and 0 mentions for Senti Biosciences. Senti Biosciences' average media sentiment score of 0.00 equaled MDxHealth'saverage media sentiment score.

Company	Overall Sentiment
Senti Biosciences	Neutral
MDxHealth	Neutral

MDxHealth has higher revenue and earnings than Senti Biosciences. MDxHealth is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$20K	498.40	-$61.44M	-$1.77	N/A
MDxHealth	$107.88M	0.29	-$33.52M	-$0.72	N/A

Senti Biosciences has a beta of 2.12, suggesting that its stock price is 112% more volatile than the broader market. Comparatively, MDxHealth has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market.

Summary

Senti Biosciences beats MDxHealth on 9 of the 16 factors compared between the two stocks.

How does Senti Biosciences compare to Kyntra Bio?

Kyntra Bio (NASDAQ:KYNB) and Senti Biosciences (NASDAQ:SNTI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

72.7% of Kyntra Bio shares are owned by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are owned by institutional investors. 4.2% of Kyntra Bio shares are owned by insiders. Comparatively, 3.1% of Senti Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Kyntra Bio currently has a consensus target price of $37.25, indicating a potential upside of 426.87%. Senti Biosciences has a consensus target price of $10.00, indicating a potential upside of 3,025.00%. Given Senti Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Senti Biosciences is more favorable than Kyntra Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Kyntra Bio has higher revenue and earnings than Senti Biosciences. Senti Biosciences is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44M	4.45	$183.45M	$45.30	0.16
Senti Biosciences	$20K	498.40	-$61.44M	-$1.77	N/A

Kyntra Bio has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market. Comparatively, Senti Biosciences has a beta of 2.12, indicating that its stock price is 112% more volatile than the broader market.

Kyntra Bio has a net margin of 2,199.13% compared to Senti Biosciences' net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-47.27%
Senti Biosciences	N/A	-1,629.80%	-119.72%

In the previous week, Kyntra Bio had 3 more articles in the media than Senti Biosciences. MarketBeat recorded 3 mentions for Kyntra Bio and 0 mentions for Senti Biosciences. Kyntra Bio's average media sentiment score of 0.67 beat Senti Biosciences' score of 0.00 indicating that Kyntra Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Kyntra Bio	Positive
Senti Biosciences	Neutral

Summary

Kyntra Bio beats Senti Biosciences on 12 of the 16 factors compared between the two stocks.

How does Senti Biosciences compare to Context Therapeutics?

Context Therapeutics (NASDAQ:CNTX) and Senti Biosciences (NASDAQ:SNTI) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

Context Therapeutics presently has a consensus price target of $6.17, indicating a potential upside of 1,575.27%. Senti Biosciences has a consensus price target of $10.00, indicating a potential upside of 3,025.00%. Given Senti Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Senti Biosciences is more favorable than Context Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

14.0% of Context Therapeutics shares are owned by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are owned by institutional investors. 4.8% of Context Therapeutics shares are owned by insiders. Comparatively, 3.1% of Senti Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Context Therapeutics has a beta of 1.69, indicating that its stock price is 69% more volatile than the broader market. Comparatively, Senti Biosciences has a beta of 2.12, indicating that its stock price is 112% more volatile than the broader market.

Context Therapeutics has higher earnings, but lower revenue than Senti Biosciences. Context Therapeutics is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A
Senti Biosciences	$20K	498.40	-$61.44M	-$1.77	N/A

Context Therapeutics' return on equity of -82.06% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-82.06%	-72.74%
Senti Biosciences	N/A	-1,629.80%	-119.72%

In the previous week, Context Therapeutics had 1 more articles in the media than Senti Biosciences. MarketBeat recorded 1 mentions for Context Therapeutics and 0 mentions for Senti Biosciences. Context Therapeutics' average media sentiment score of 0.00 equaled Senti Biosciences'average media sentiment score.

Company	Overall Sentiment
Context Therapeutics	Neutral
Senti Biosciences	Neutral

Summary

Context Therapeutics and Senti Biosciences tied by winning 7 of the 14 factors compared between the two stocks.

How does Senti Biosciences compare to Aligos Therapeutics?

Senti Biosciences (NASDAQ:SNTI) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Senti Biosciences has a beta of 2.12, meaning that its stock price is 112% more volatile than the broader market. Comparatively, Aligos Therapeutics has a beta of 2.34, meaning that its stock price is 134% more volatile than the broader market.

In the previous week, Aligos Therapeutics had 2 more articles in the media than Senti Biosciences. MarketBeat recorded 2 mentions for Aligos Therapeutics and 0 mentions for Senti Biosciences. Senti Biosciences' average media sentiment score of 0.00 equaled Aligos Therapeutics'average media sentiment score.

Company	Overall Sentiment
Senti Biosciences	Neutral
Aligos Therapeutics	Neutral

Senti Biosciences has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -241.01%. Aligos Therapeutics' return on equity of -160.72% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-1,629.80%	-119.72%
Aligos Therapeutics	-241.01%	-160.72%	-92.30%

Aligos Therapeutics has higher revenue and earnings than Senti Biosciences. Aligos Therapeutics is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$20K	498.40	-$61.44M	-$1.77	N/A
Aligos Therapeutics	$2.19M	14.93	-$24.19M	-$7.30	N/A

Senti Biosciences currently has a consensus target price of $10.00, indicating a potential upside of 3,025.00%. Aligos Therapeutics has a consensus target price of $38.50, indicating a potential upside of 634.73%. Given Senti Biosciences' higher probable upside, equities analysts clearly believe Senti Biosciences is more favorable than Aligos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

25.7% of Senti Biosciences shares are owned by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are owned by institutional investors. 3.1% of Senti Biosciences shares are owned by company insiders. Comparatively, 7.8% of Aligos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Aligos Therapeutics beats Senti Biosciences on 10 of the 15 factors compared between the two stocks.

How does Senti Biosciences compare to Gossamer Bio?

Gossamer Bio (NASDAQ:GOSS) and Senti Biosciences (NASDAQ:SNTI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

Senti Biosciences has lower revenue, but higher earnings than Gossamer Bio. Gossamer Bio is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$53.29M	0.59	-$170.37M	-$56.00	N/A
Senti Biosciences	$20K	498.40	-$61.44M	-$1.77	N/A

Gossamer Bio presently has a consensus price target of $256.00, suggesting a potential upside of 2,285.83%. Senti Biosciences has a consensus price target of $10.00, suggesting a potential upside of 3,025.00%. Given Senti Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Senti Biosciences is more favorable than Gossamer Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are held by institutional investors. 3.7% of Gossamer Bio shares are held by company insiders. Comparatively, 3.1% of Senti Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Gossamer Bio had 4 more articles in the media than Senti Biosciences. MarketBeat recorded 4 mentions for Gossamer Bio and 0 mentions for Senti Biosciences. Gossamer Bio's average media sentiment score of 0.11 beat Senti Biosciences' score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Gossamer Bio	Neutral
Senti Biosciences	Neutral

Senti Biosciences has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Gossamer Bio's return on equity of 0.00% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-235.00%	N/A	-112.04%
Senti Biosciences	N/A	-1,629.80%	-119.72%

Gossamer Bio has a beta of 2, indicating that its stock price is 100% more volatile than the broader market. Comparatively, Senti Biosciences has a beta of 2.12, indicating that its stock price is 112% more volatile than the broader market.

Summary

Senti Biosciences beats Gossamer Bio on 9 of the 17 factors compared between the two stocks.

Get Senti Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNTI vs. The Competition

Export

Metric	Senti Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.97M	$3.88B	$7.24B	$12.95B
Dividend Yield	N/A	3.64%	2.57%	12.80%
P/E Ratio	-0.18	14.23	275.49	25.40
Price / Sales	498.40	1,440.84	644.44	86.30
Price / Cash	N/A	108.90	76.25	51.42
Price / Book	1.78	15.45	10.46	6.33
Net Income	-$61.44M	-$22.86M	$3.49B	$358.33M
7 Day Performance	4.58%	-1.21%	0.59%	1.12%
1 Month Performance	-26.61%	-3.29%	-1.74%	-2.39%
1 Year Performance	-76.30%	37.74%	18.13%	5.35%

Senti Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNTI Senti Biosciences	1.6728 of 5 stars	$0.32 +2.2%	$10.00 +3,025.0%	-76.3%	$9.97M	$20K	N/A	39	Gap Up
MDXH MDxHealth	2.1118 of 5 stars	$0.67 -4.8%	$2.17 +221.8%	-84.8%	$35.01M	$107.88M	N/A	300	News Coverage
KYNB Kyntra Bio	3.8746 of 5 stars	$7.77 -3.2%	$36.00 +363.3%	N/A	$32.51M	$6.44M	0.17	570	News Coverage Analyst Upgrade Gap Up
CNTX Context Therapeutics	2.3865 of 5 stars	$0.36 +3.8%	$6.17 +1,592.3%	-62.0%	$32.25M	N/A	N/A	7	News Coverage
ALGS Aligos Therapeutics	2.1854 of 5 stars	$4.99 -1.0%	$38.50 +671.5%	-45.8%	$31.47M	$2.19M	N/A	90	News Coverage Analyst Downgrade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNTI) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Senti Biosciences (SNTI) Competitors

SNTI vs. MDXH, KYNB, CNTX, ALGS, and GOSS

How does Senti Biosciences compare to MDxHealth?

Summary

How does Senti Biosciences compare to Kyntra Bio?

Summary

How does Senti Biosciences compare to Context Therapeutics?

Summary

How does Senti Biosciences compare to Aligos Therapeutics?

Summary

How does Senti Biosciences compare to Gossamer Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNTI vs. The Competition

Senti Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Senti Biosciences (SNTI) Competitors

SNTI vs. MDXH, KYNB, CNTX, ALGS, and GOSS

How does Senti Biosciences compare to MDxHealth?

Do institutionals and insiders have more ownership in SNTI or MDXH?

Do analysts rate SNTI or MDXH?

Is SNTI or MDXH more profitable?

Does the media favor SNTI or MDXH?

Which has better earnings & valuation, SNTI or MDXH?

Which has more volatility & risk, SNTI or MDXH?

Summary

How does Senti Biosciences compare to Kyntra Bio?

Do institutionals & insiders believe in KYNB or SNTI?

Do analysts rate KYNB or SNTI?

Which has stronger earnings & valuation, KYNB or SNTI?

Which has more volatility and risk, KYNB or SNTI?

Is KYNB or SNTI more profitable?

Does the media prefer KYNB or SNTI?

Summary

How does Senti Biosciences compare to Context Therapeutics?

Do analysts rate CNTX or SNTI?

Do insiders & institutionals believe in CNTX or SNTI?

Which has more risk & volatility, CNTX or SNTI?

Which has higher valuation & earnings, CNTX or SNTI?

Is CNTX or SNTI more profitable?

Does the media prefer CNTX or SNTI?

Summary

How does Senti Biosciences compare to Aligos Therapeutics?

Which has more volatility & risk, SNTI or ALGS?

Does the media prefer SNTI or ALGS?

Is SNTI or ALGS more profitable?

Which has higher valuation & earnings, SNTI or ALGS?

Do analysts rate SNTI or ALGS?

Do insiders & institutionals believe in SNTI or ALGS?

Summary

How does Senti Biosciences compare to Gossamer Bio?

Which has preferable earnings and valuation, GOSS or SNTI?

Do analysts rate GOSS or SNTI?

Do insiders & institutionals hold more shares of GOSS or SNTI?

Does the media refer more to GOSS or SNTI?

Is GOSS or SNTI more profitable?

Which has more risk & volatility, GOSS or SNTI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNTI vs. The Competition

Senti Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools